Impact of the ongoing worldwide shortage of verteporfin (Visudyne?) on the visual function of patients with chronic central serous chorioretinopathy

Acta OphthalmologicaEarly View LETTER TO THE EDITOR Impact of the ongoing worldwide shortage of verteporfin (Visudyne®) on the visual function of patients with chronic central serous chorioretinopathy Chrysanthi Tsika, Chrysanthi Tsika orcid.org/0000-0001-9695-7162 Southampton Eye Unit, University of Southampton, University Hospital of Southampton, Southampton, Hampshire, UKSearch for more papers by this authorMoin D. Mohamed, Moin D. Mohamed Department of Ophthalmology, Guy's & St Thomas' NHS Foundation Trust, London, UKSearch for more papers by this authorAndrew J. Lotery, Corresponding Author Andrew J. Lotery [email protected] orcid.org/0000-0001-5541-4305 Southampton Eye Unit, University of Southampton, University Hospital of Southampton, Southampton, Hampshire, UK Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK Correspondence Andrew J. Lotery University Hospital of Southampton, Tremona Rd, SO16 6YD Southampton, UK. Email: [email protected]Search for more papers by this author Chrysanthi Tsika, Chrysanthi Tsika orcid.org/0000-0001-9695-7162 Southampton Eye Unit, University of Southampton, University Hospital of Southampton, Southampton, Hampshire, UKSearch for more papers by this authorMoin D. Mohamed, Moin D. Mohamed Department of Ophthalmology, Guy's & St Thomas' NHS Foundation Trust, London, UKSearch for more papers by this authorAndrew J. Lotery, Corresponding Author Andrew J. Lotery [email protected] orcid.org/0000-0001-5541-4305 Southampton Eye Unit, University of Southampton, University Hospital of Southampton, Southampton, Hampshire, UK Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK Correspondence Andrew J. Lotery University Hospital of Southampton, Tremona Rd, SO16 6YD Southampton, UK. Email: [email protected]Search for more papers by this author First published: 19 May 2023 https://doi.org/10.1111/aos.15714Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES Lotery, A., Sivaprasad, S., O'Connell, A., Harris, R.A., Culliford, L., Ellis, L. et al. (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, 395, 294– 303. Sirks, M.J., van Dijk, E.H.C., Rosenberg, N., Hollak, C.E.M., Aslanis, S., Cheung, C.M.G. et al. (2022) Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmologica, 100(7), e1522– e1532. van Dijk, E.H.C., Fauser, S., Breukink, M.B., Blanco-Garavito, R., Groenewoud, J.M.M., Keunen, J.E.E. et al. (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology, 125, 1547– 1555. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation